ATE318312T1 - Monoklonaler anti-idiotypischer antikörper 11d10 aus der maus und methoden zu dessen verwendung - Google Patents

Monoklonaler anti-idiotypischer antikörper 11d10 aus der maus und methoden zu dessen verwendung

Info

Publication number
ATE318312T1
ATE318312T1 AT96945090T AT96945090T ATE318312T1 AT E318312 T1 ATE318312 T1 AT E318312T1 AT 96945090 T AT96945090 T AT 96945090T AT 96945090 T AT96945090 T AT 96945090T AT E318312 T1 ATE318312 T1 AT E318312T1
Authority
AT
Austria
Prior art keywords
hmfg
monoclonal anti
hybridoma
produces
mouse
Prior art date
Application number
AT96945090T
Other languages
English (en)
Inventor
Malaya Chatterjee
Kenneth A Foon
Sunil K Chatterjee
Original Assignee
Univ Kentucky Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Kentucky Res Found filed Critical Univ Kentucky Res Found
Application granted granted Critical
Publication of ATE318312T1 publication Critical patent/ATE318312T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • C07K16/4258—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig
    • C07K16/4266—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig against anti-tumor receptor Ig
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/686—Anti-idiotype
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/023—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a poxvirus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4725—Mucins, e.g. human intestinal mucin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT96945090T 1995-12-20 1996-12-19 Monoklonaler anti-idiotypischer antikörper 11d10 aus der maus und methoden zu dessen verwendung ATE318312T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US57576295A 1995-12-20 1995-12-20
US59196596A 1996-01-29 1996-01-29
US08/766,350 US6949244B1 (en) 1995-12-20 1996-12-13 Murine monoclonal anti-idiotype antibody 11D10 and methods of use thereof

Publications (1)

Publication Number Publication Date
ATE318312T1 true ATE318312T1 (de) 2006-03-15

Family

ID=35657434

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96945090T ATE318312T1 (de) 1995-12-20 1996-12-19 Monoklonaler anti-idiotypischer antikörper 11d10 aus der maus und methoden zu dessen verwendung

Country Status (9)

Country Link
US (3) US6949244B1 (de)
EP (1) EP0876486B1 (de)
AT (1) ATE318312T1 (de)
AU (1) AU731063B2 (de)
BR (1) BR9612093A (de)
CA (1) CA2239799C (de)
DE (1) DE69635843T2 (de)
ES (1) ES2259184T3 (de)
WO (1) WO1997022699A2 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020098190A1 (en) * 1997-06-13 2002-07-25 Malaya Chatterjee Compositions and methods for treating tumors bearing HMFG and CEA antigens
US6274143B1 (en) 1997-06-13 2001-08-14 Malaya Chatterjee Methods of delaying development of HMFG-associated tumors using anti-idiotype antibody 11D10
US6913749B2 (en) * 1998-11-02 2005-07-05 Resistentia Pharmaceuticals Ab Immunogenic polypeptides for inducing anti-self IgE responses
AT407958B (de) * 1999-02-11 2001-07-25 Immuno Ag Inaktivierte influenza-virus-vakzine zur nasalen oder oralen applikation
US7902338B2 (en) 2003-07-31 2011-03-08 Immunomedics, Inc. Anti-CD19 antibodies
CA2589009A1 (en) * 2004-11-24 2006-06-01 Health Research Inc. Method for identifying and designing immunogenic peptides
US20070134784A1 (en) * 2005-12-09 2007-06-14 Halverson Kurt J Microreplicated microarrays
EP1976878A4 (de) * 2006-01-30 2010-06-02 Fred Hutchinson Cancer Res Fou Folge aus der variablen stro-1-antikörperregion
US8501417B2 (en) 2007-06-26 2013-08-06 Vanderbilt University Immunological compositions as cancer biomarkers and/or therapeutics
ES2738700T3 (es) 2009-02-13 2020-01-24 Immunomedics Inc Inmunoconjugados con un enlace escindible intracelularmente
EP2478110B1 (de) 2009-09-16 2016-01-06 Immunomedics, Inc. Klasse-i-anti-cea-antikörper und verwendungen davon
CA2782194C (en) 2009-12-02 2018-01-16 Immunomedics, Inc. Combination of radiolabelled antibodies (rait) and antibody-drug conjugates (adc) for treatment of pancreatic cancer
EP2542567B1 (de) 2010-03-05 2020-02-12 Boehringer Ingelheim International Gmbh Selektive anreicherung von antikörpern
CN103501825B (zh) 2011-05-02 2017-03-15 免疫医疗公司 用于小体积施用的同种异型选择的抗体的超滤浓缩
EP2885002A4 (de) 2012-08-14 2016-04-20 Ibc Pharmaceuticals Inc Umleitung t-zell-bispezifischer antikörper zur behandlung von krankheiten
AU2013360335B2 (en) 2012-12-13 2017-12-07 Immunomedics, Inc. Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
EP3107577B1 (de) 2014-02-21 2024-03-20 IBC Pharmaceuticals, Inc. Krankheitstherapie durch induktion einer immunantwort gegen trop-2-exprimierende zellen
CN106029098A (zh) 2014-02-25 2016-10-12 免疫医疗公司 人源化rfb4抗cd22抗体
WO2015200260A1 (en) 2014-06-24 2015-12-30 Immunomedics, Inc. Anti-histone therapy for vascular necrosis in severe glomerulonephritis
CA2961774C (en) 2014-10-07 2023-05-23 Immunomedics, Inc. Neoadjuvant use of antibody-drug conjugates
US9797907B2 (en) 2015-04-22 2017-10-24 Immunomedics, Inc. Isolation, detection, diagnosis and/or characterization of circulating Trop-2-positive cancer cells
JP6980980B2 (ja) 2015-06-25 2021-12-15 イミューノメディクス、インコーポレイテッドImmunomedics, Inc. 抗ｈｌａ‐ｄｒまたは抗ｔｒｏｐ‐２抗体と微小管阻害剤、ｐａｒｐ阻害剤、ブルトンキナーゼ阻害剤またはホスホイノシチド３‐キナーゼ阻害剤との併用は癌の治療効果を有意に改善する
EP3316885B1 (de) 2015-07-01 2021-06-23 Immunomedics, Inc. Antikörper-sn-38-immunkonjugate mit einem cl2a-linker
WO2021054262A1 (en) * 2019-09-20 2021-03-25 Terumo Kabushiki Kaisha Method for evaluating a coating state of either an adsorbent of a sample protein or an adsorption state of a sample protein
JPWO2022239720A1 (de) 2021-05-10 2022-11-17

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
JPS54140710A (en) 1978-03-10 1979-11-01 Mitsui Toatsu Chem Inc Anti-tumor substance and its preparation
US4436728A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4693966A (en) 1983-03-11 1987-09-15 Sloan-Kettering Institute For Cancer Research Human monoclonal antibodies from lymphocytes of patients with malignant melanoma
EP0291636A1 (de) 1983-11-07 1988-11-23 The Wistar Institute Von Anti-Idiotyp-Antikörpern induzierte Immunreaktion gegen Viren
US5053224A (en) 1983-11-07 1991-10-01 Hilary Koprowski Induction of antibody response to solid tumors with anti-idiotype antibodies
US5171568A (en) 1984-04-06 1992-12-15 Chiron Corporation Recombinant herpes simplex gb-gd vaccine
US4675287A (en) 1984-07-26 1987-06-23 Scripps Clinic And Research Foundation Monoclonal antibody directed to human ganglioside GD2
US4722840A (en) 1984-09-12 1988-02-02 Chiron Corporation Hybrid particle immunogens
US4754065A (en) 1984-12-18 1988-06-28 Cetus Corporation Precursor to nucleic acid probe
US4918164A (en) 1987-09-10 1990-04-17 Oncogen Tumor immunotherapy using anti-idiotypic antibodies
US4935495A (en) 1984-12-21 1990-06-19 Oncogen Monoclonal antibodies to the L6 glycolipid antigenic determinant found on human non-small cell lung carcinomas
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4904596A (en) 1985-08-07 1990-02-27 Fred Hutchinson Cancer Research Center Hybridoma antibody (FH6) defining a human cancer-associated difucoganglioside
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
US5009995A (en) 1986-10-27 1991-04-23 Sloan-Kettering Institute For Cancer Research Monoclonal antibodies to melanoma cells
US4996490A (en) * 1986-11-18 1991-02-26 Atlantic Richfield Company Microwave apparatus and method for measuring fluid mixtures
US4849509A (en) 1987-02-20 1989-07-18 The Wistar Institute Monoclonal antibodies against melanoma-associated antigens and hybrid cell lines producing these antibodies
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
AU3049189A (en) 1988-02-08 1989-08-25 John Muir Cancer & Aging Institute Monoclonal antibody specific to a novel mucin-like glycoprotein surface antigen on human carcinoma cells
JPH01207920A (ja) 1988-02-16 1989-08-21 Oki Electric Ind Co Ltd ＩｎＰ半導体薄膜の製造方法
GB8812137D0 (en) 1988-05-23 1988-06-29 Imp Cancer Res Tech Antibodies
US5242824A (en) 1988-12-22 1993-09-07 Oncogen Monoclonal antibody to human carcinomas
US5407684A (en) 1988-12-30 1995-04-18 Virginia Commonwealth University Use of DHEA as a medicinal
US5077284A (en) 1988-12-30 1991-12-31 Loria Roger M Use of dehydroepiandrosterone to improve immune response
US5240833A (en) 1989-01-30 1993-08-31 The Biomembrane Institute Method for the production of monoclonal antibodies directed to tumor-associated gangliosides and fucogangliosides
US5134075A (en) 1989-02-17 1992-07-28 Oncogen Limited Partnership Monoclonal antibody to novel antigen associated with human tumors
US5270202A (en) 1989-11-03 1993-12-14 Syamal Raychaudhuri Anti-idiotypic antibodies to human melanoma-associated proteoglycan antigen
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
SG46445A1 (en) 1990-01-26 1998-02-20 Immunomedics Inc Vaccines against cancer and infectious diseases
JPH05503848A (ja) 1990-02-01 1993-06-24 アクゾ・エヌ・ヴエー 細胞の培養方法
WO1991016924A1 (en) 1990-05-10 1991-11-14 The Dana-Farber Cancer Institute Enhancing the association of exogenous peptides with class i mhc molecules on immune system cells
US5208146A (en) 1990-11-05 1993-05-04 The Regents Of The University Of California Murine monoclonal anti-idiotype antibodies
ES2178635T3 (es) 1990-11-09 2003-01-01 Stephen D Gillies Inmunoconjugados de citoquinas.
GB9105992D0 (en) 1991-03-21 1991-05-08 Smithkline Beecham Biolog Vaccine
AU2690192A (en) 1991-09-19 1993-04-27 Lionel A. Manson Tumor immunotherapy utilizing a method of overcoming the resistance of a progressively growing tumor
WO1994005329A1 (en) 1992-08-31 1994-03-17 Jenner Technologies Stimulation of an antitumor t-cell response using anti-idiotypic antibodies
WO1994011508A2 (en) 1992-11-13 1994-05-26 Cancer Research Fund Of Contra Costa Polypeptides with specificity for neoplasias, kit, and diagnostic, vaccination, and therapeutic methods
US5472693A (en) * 1993-02-16 1995-12-05 The Dow Chemical Company Family of anti-carcinoembryonic antigen chimeric antibodies
US5840299A (en) * 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
US6274143B1 (en) 1997-06-13 2001-08-14 Malaya Chatterjee Methods of delaying development of HMFG-associated tumors using anti-idiotype antibody 11D10
DK1345959T3 (da) 2000-11-20 2011-09-05 Univ Illinois Membranscaffoldproteiner

Also Published As

Publication number Publication date
US7399849B2 (en) 2008-07-15
DE69635843T2 (de) 2006-10-05
WO1997022699A3 (en) 1997-09-04
CA2239799C (en) 2008-08-12
US20060018895A1 (en) 2006-01-26
AU1354297A (en) 1997-07-14
BR9612093A (pt) 1999-12-28
WO1997022699A2 (en) 1997-06-26
AU731063B2 (en) 2001-03-22
CA2239799A1 (en) 1997-06-26
EP0876486A2 (de) 1998-11-11
ES2259184T3 (es) 2006-09-16
US6949244B1 (en) 2005-09-27
EP0876486B1 (de) 2006-02-22
DE69635843D1 (de) 2006-04-27
US7083943B1 (en) 2006-08-01

Similar Documents

Publication Publication Date Title
ATE318312T1 (de) Monoklonaler anti-idiotypischer antikörper 11d10 aus der maus und methoden zu dessen verwendung
ATE237687T1 (de) Rekombinierte sequenzen des monoklonalen anti- idiotypischen antikörpers 3h1, diean dem menschlichen karzioembyonischen antigen liiert sind
EP0552296A4 (en) Mouse monoclonal antibodies
DE69942671D1 (de) Humanisierte antikoerper gegen gamma-interferon
ATE248605T1 (de) Für e-selectin und p-selectin spezifische kreuzreaktive monoklonale antikörper
DK0784683T3 (da) TIE-2-ligander, fremgangsmåder til dannelse af disse og anvendelser deraf
HUP0302532A2 (hu) Petefészekrák terápiájában és diagnosztizálásában alkalmazható készítmények és eljárások
EA200301098A1 (ru) Ассоциированные с ганглиозидами рекомбинантные антитела и их применение в диагностике и лечении опухолей
ES2098274T3 (es) Anticuerpos monoclonales.
ATE370235T1 (de) Rekombinantpeptide hergeleitet vom mc3 antikörper gegen ba46, verfahren zu deren verwendung und verfahren zur humanisierung von antikörperpeptiden
ATE442157T1 (de) Verwendung von anti-cd3 monoklonale antikírper und il-5 zur behandlung von autoimmunkrankheiten
DK0466818T3 (da) Monoklonalt antistof der genkender et glycoprotein fra mucin-antigen fra membranen af fedtkugler fra human mælk
DE69840326D1 (de) Steigerung der immunantwort unter verwendung von zielgerichteten molekülen
NO972522L (no) Monoklonale antistoffer med immunoundertrykkende aktivitet
DK102589D0 (da) Antigen, der genkendes af mca 16-88
DE69119591D1 (de) Das von mca-28a32 erkannte antigen
DE59207362D1 (de) Monoklonale Antikörper gegen den Plasmin-Antiplasmin Komplex, Verfahren zu ihrer Herstellung sowie ihre Verwendung

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties